Development of an activity-based chemiluminogenic probe for y-glutamylcyclotransferase

Yukie Nohara^[a], Keiko Taniguchi^[b], Hiromi li^[c], Shun Masuda^[a], Hiroko Kawakami^[a], Masakatsu Matsumoto^[d], Yasunao Hattori^[e], Susumu Kageyama^[f], Toshiyuki Sakai^[b], Susumu Nakata* ^[c], Taku Yoshiya*^[a, g]

^[a] Peptide Institute, Inc., 7-2-9 Saito-Asagi, Ibaraki-shi, Osaka 567-0085, Japan.

^[b] Department of Drug Discovery Medicine, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Kamigyo-ku, Kyoto 602-8566, Japan.

^[c] Laboratory of Clinical Oncology, Kyoto Pharmaceutical University, Misasagi-Nakauchi-cho 5, Yamashina-ku, Kyoto 607-8414, Japan.

^[d] Department of Chemistry, Kanagawa University, 3-27-1 Rokkakubashi, Kanagawa-ku, Yokohama, Kanagawa, 221-8686, Japan.

^[e] Center for Instrumental Analysis, Kyoto Pharmaceutical University, Misasagi-Schichonocho 1, Yamashina-ku, Kyoto 607-8412, Japan.


^[f] Department of Urology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan.

^[g] Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita-shi, Osaka 565-0871, Japan.


Contents

- Supplemental synthetic schemes P. 2
- Stability evaluation of MAM-LISA-103
 P. 3
- NMR spectra P. 4


Supplemental synthetic schemes



Scheme S1. Synthesis route of compound **1**. Reagents and conditions: i) NsCl, K₂CO₃, THF/H₂O (2/1), ii) EtI, K₂CO₃, DMF, iii) 4.0 M HCl/dioxane, 0 °C, iv) Boc-Glu-OtBu, EDC•HCl, HOBt, DMF/H₂O (95/5), v) LiOH•H₂O, thioglycolic acid, DMF.



Scheme S2. Synthesis route of compound 2. Reagents and conditions: i) NaH, THF, ii) PCC, CH₂Cl₂, iii) LDA, THF, iv) Cl₂CHOCH₃, AgOTf, CH₂Cl₂, v) BBr₃, CH₂Cl₂, vi) PPh₃CHCOOEt, *N*,*N*-diethylaniline, vii) AlCl₃, CH₂Cl₂.



Scheme S3. Synthesis route of compound 4. Reagents and conditions: i) NsCl, K_2CO_3 , THF/H₂O (2/1), ii) EtI, K_2CO_3 , DMF, iii) 4.0 M HCl/dioxane, 0 °C, iv) Boc-Glu-OMe, EDC•HCl, HOBt, DMF/H₂O (95/5), v) K_2CO_3 , 4-mercaptophenylacetic acid, DMF.

Stability evaluation of MAM-LISA-103

Compared with LISA-103, we noticed unstability of MAM-LISA-103 during storage as a lyophilized powder. After consideration of several conditions, we finally found that co-existence of sucrose as a diluent can prevent decomposition of MAM-LISA-103 while the reason is unclear. As shown in Fig S1, at room temperature (accelerated test), 9% was decomposed after 7 h in the presence of sucrose, while 34% was decomposed without sucrose. Based on these results, MAM-LISA-103 was stored as a lyophilized powder with sucrose. Eventually, only 0.3% was decomposed after 6 months at -20 °C.




Fig. S1 Stability comparison study of MAM-LISA-103. The decomposition ratio of MAM-LISA-103 in the lyophilized powder with or without sucrose at room temperature was evaluated by HPLC.

NMR spectra

